Vaxart Finalizes $49.7M At-The-Market Offering Amid Going Concern Warning and Significant Dilution

summarizeSummary

Vaxart has finalized an At-The-Market offering to raise up to $49.7 million, a critical move to address its going concern warning and extend its operational runway, but it comes with significant potential shareholder dilution.

check_boxKey Events

• Finalizes At-The-Market Offering

  Vaxart has finalized an At-The-Market (ATM) offering to sell up to $49,772,479 of common stock through sales agents. This follows the S-3 registration filed on 2026-04-16, which initially disclosed the ATM program.

• Addresses Going Concern Warning

  The company explicitly states that its recurring losses and negative cash flows raise substantial doubt about its ability to continue as a going concern, with current funds projected to last only into the second quarter of 2027. The proceeds from this offering are intended for general corporate purposes, including working capital, operating expenses, and capital expenditures, to extend its operational runway.

• Significant Potential Dilution

  If the offering is fully utilized at an assumed price of $0.63 per share, it could result in the issuance of approximately 79 million new shares, representing a substantial increase in outstanding shares and significant dilution for current stockholders.

• Trading on OTCQX After Nasdaq Delisting

  Vaxart's common stock was delisted from Nasdaq in November 2025 and now trades on the OTCQX Best Market, indicating a challenging market environment for the company.

auto_awesomeAnalysis

Vaxart, a clinical-stage biotechnology company, has finalized the terms for an At-The-Market (ATM) offering to sell up to $49.7 million of common stock. This prospectus supplement operationalizes the ATM program previously disclosed in the S-3 registration filed on 2026-04-16. The company explicitly states that its recurring losses and negative cash flows raise substantial doubt about its ability to continue as a going concern, making this capital raise critical for funding operations into Q2 2027. The offering, if fully utilized at the assumed price of $0.63 per share, could result in the issuance of approximately 79 million new shares, representing significant potential dilution for existing shareholders. The stock was delisted from Nasdaq in November 2025 and now trades on the OTCQX, further highlighting the company's challenging financial position.